Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Gongyan Chen et al.|The Lancet Respiratory Medicine|2020Cited by 504
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Caicun Zhou, Jianhua Chen et al.|Journal of Thoracic Oncology|2021Cited by 311
Effect of airborne particulate matter of 2.5 μm or less on preterm birth: A national birth cohort study in ChinaQin Li, Xu Ma, Donghai Yan et al.|Environment International|2018Cited by 73
Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.Fenlai Tan, Yan Sun, Aiqin Gu et al.|Journal of Clinical Oncology|2013Cited by 5